Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom

BMC Infectious Diseases

Christopher T. Bauch²  Genevieve Meier³  Ayman Chit⁵  Afisi Ismaila¹  Edward W. Thommes⁴ 

[1]Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

[2]Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada

[3]GSK Vaccines, Wavre, Belgium

[4]Department of Mathematics & Statistics, University of Guelph, Guelph, Ontario, Canada

[5]Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada

关键词: TIV;    QIV;    Dynamic;    Influenza;    UK;    Canada;    Cost-effectiveness;    Transmission;    Vaccination;   

Others  :  1232748
DOI  :  10.1186/s12879-015-1193-4

 received in 2015-04-15, accepted in 2015-10-07,  发布年份 2015

【 摘 要 】

Background

The adoption of quadrivalent influenza vaccine (QIV) to replace trivalent influenza vaccine (TIV) in immunization programs is growing worldwide, thus helping to address the problem of influenza B lineage mismatch. However, the price per dose of QIV is higher than that of TIV. In such circumstances, cost-effectiveness analyses provide important and relevant information to inform national health recommendations and implementation decisions. This analysis assessed potential vaccine impacts and cost-effectiveness of a country-wide switch from TIV to QIV, in Canada and the UK, from a third-party payer perspective.

Methods

An age-stratified, dynamic four-strain transmission model which incorporates strain interaction, transmission-rate seasonality and age-specific mixing in the population was used. Model input data were obtained from published literature and online databases. In Canada, we evaluated a switch from TIV to QIV in the entire population. For the UK, we considered two strategies: Children aged 2–17 years who receive the live-attenuated influenza vaccine (LAIV) switch to the quadrivalent formulation (QLAIV), while individuals aged > 18 years switch from TIV to QIV. Two different vaccination uptake scenarios in children (UK1 and UK2, which differ in the vaccine uptake level) were considered. Health and cost outcomes for both vaccination strategies, and the cost-effectiveness of switching from TIV/LAIV to QIV/QLAIV, were estimated from the payer perspective. For Canada and the UK, cost and outcomes were discounted using 5 % and 3.5 % per year, respectively.

Results

Overall, in an average influenza season, our model predicts that a nationwide switch from TIV to QIV would prevent 4.6 % influenza cases, 4.9 % general practitioner (GP) visits, 5.7 % each of emergency room (ER) visits and hospitalizations, and 6.8 % deaths in Canada. In the UK (UK1/UK2), implementing QIV would prevent 1.4 %/1.8 % of influenza cases, 1.6 %/2.0 % each of GP and ER visits, 1.5 %/1.9 % of hospitalizations and 4.3 %/4.9 % of deaths. Discounted incremental cost-utility ratios of $7,961 and £7,989/£7,234 per quality-adjusted life-year (QALY) gained are estimated for Canada and the UK (UK1/UK2), both of which are well within their respective cost-effectiveness threshold values.

Conclusions

Switching from TIV to QIV is expected to be a cost-effective strategy to further reduce the burden of influenza in both countries.

【 授权许可】

   
2015 Thommes et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]World Health Organization position paper on influenza vaccines. Wkly Epidemiol Record 2005; 33, 279–287.
• [2]Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012; 8(1):81-8.
• [3]Daley AJ, Nallusamy R, Isaacs D. Comparison of influenza A and influenza B virus infection in hospitalized children. J Paediatr Child Health. 2000; 36(4):332-5.
• [4]Hite LK, Glezen WP, Demmler GJ, Munoz FM. Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int J Infect Dis. 2007; 11(1):40-7.
• [5]Ng S, Cowling BJ, Fang VJ, Chan KH, Ip DKM, Cheng CKY, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis. 2010;50(5):707–14. doi:10.1086/650458.
• [6]Irving SA, Patel DC, Kieke BA, Donahue JG, Vandermause MF, Shay DK, et al. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004–2005 through 2007–2008. Influenza Other Respir Viruses. 2012;6(1):37–43. doi:10.1111/j.1750-2659.2011.00263.x.
• [7]Recommendations of the Advisory Committee on Immunization Practices--United States, 2013–2014. MMWR Recomm Rep. 2013; 62(Rr-07):1-43.
• [8]Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153. doi:10.1186/1741-7015-11-153.
• [9]DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012; 31(1):49-57.
• [10]Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010; 28 Suppl 4:D45-53.
• [11]Lo YC, Chuang JH, Kuo HW, Huang WT, Hsu YF, Liu MT, et al. Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011–12 season. PLoS One. 2013;8(3), e58222. doi:10.1371/journal.pone.0058222.
• [12]Beran J, Peeters M, Dewe W, Raupachová J, Hobzová L, Devaster JM. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis. 2013;13:224. doi:10.1186/1471-2334-13-224.
• [13]Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years. J Infect Dis. 2013;207(12):1878–87. doi:10.1093/infdis/jit091.
• [14]Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged > =18 years. BMC Infect Dis. 2013;13(1):343. doi:10.1186/1471-2334-13-343.
• [15]Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Keith S. Reisinger, Naresh Aggarwal et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis. 2013;208(4):544–53. doi:10.1093/infdis/jit263.
• [16]Kim TH. Seasonal influenza and vaccine herd effect. Clin Exp Vaccine Res. 2014; 3(2):128-32.
• [17]Public Health Agency of Canada. Public Funding for Influenza Vaccination by Province/Territory (as of September, 2014). Available at: http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/fluvacc-eng.php. Accessed on: 1-Dec-2014.
• [18]Pebody RG, Green HK, Andrews N, Zhao H, Boddington N, Bawa Z, et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. Euro Surveill. 2014;19(22):20823.
• [19]Public Health England. Flu Vaccination in Pilot Areas 2014/15. Stakeholder briefing, August 2014. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/343878/Stakeholder_briefing_14-15_F.pdf. Accessed on: 1-December-2014.
• [20]Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine. 2012; 30(52):7443-6.
• [21]Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012; 30(11):1993-8.
• [22]Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One. 2014; 9(6): Article ID e98437
• [23]Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother. 2014;10(5):1171–1180.
• [24]Tarride JE, Burke N, Von Keyserlingk C, O’Reilly D, Xie F, Goeree R. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. Clinicoecon Outcomes Res. 2012;4:287–98. doi:10.2147/ceor.s33444.
• [25]Postma MJ. Dynamic modeling for pandemic influenza. Expert Rev Vaccines. 2012; 11(5):543-6.
• [26]Thommes EW, Chit A, Meier GC, Bauch CT. Examining Ontario's universal influenza immunization program with a multi-strain dynamic model. Vaccine. 2014; 32(39):5098-117.
• [27]Pitman RJ, White LJ, Sculpher M. Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales. Vaccine. 2012; 30(6):1208-24.
• [28]Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine. 2008;26(41):5321–30. doi:10.1016/j.vaccine.2008.06.101.
• [29]Marjoram P, Molitor J, Plagnol V, Tavaré S. Markov chain Monte Carlo without likelihoods. Proc Natl Acad Sci. 2003; 100(26):15324-8.
• [30]Tully SP, Anonychuk AM, Sanchez DM, Galvani AP, Bauch CT. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine. 2012;30(2):425–35. doi:10.1016/j.vaccine.2011.10.067.
• [31]Van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007; 165(7):762-75.
• [32]Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003;7(35):iii-iv, xi-xiii, 1–170.
• [33]Government of Canada. Statistics Canada. Available at: http://www5.statcan.gc.ca/cansim/. Accessed on: 1-April-2014.
• [34]Office for National Statisitics. Available at: http://www.ons.gov.uk/ons/index.html. Accessed on: 1-April-2014.
• [35]Zagheni E, Billari FC, Manfredi P, Melegaro A, Mossong J, Edmunds WJ. Using time-use data to parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol. 2008;168(9):1082–90. doi:10.1093/aje/kwn220.
• [36]Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3), e74. doi:10.1371/journal.pmed.0050074.
• [37]Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086–96. doi:10.1016/j.vaccine.2007.03.046.
• [38]Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess. 2009;13(11):iii. doi:10.3310/hta13110. ix-xii, 1–246.
• [39]Meier CR, Napalkov PN, Wegmuller Y, Jefferson T, Jick H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis. 2000;19(11):834–42.
• [40]Statistics Canada. Complete Life Table, Canada, 200–2002: females. Available at: http://www.statcan.gc.ca/pub/84-537-x/t/pdf/4198611-eng.pdf. Accessed on: 16-November-2014.
• [41]Statistics Canada. Complete Life Table, Canada, 200–2002: males. Available at: http://www.statcan.gc.ca/pub/84-537-x/t/pdf/4198612-eng.pdf. Accessed on: 16-November-2014.
• [42]Office for National Statistics, Interim life tables 2010–2012. Available at: http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-325699. Accessed on: 16-November-2014
• [43]Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999; 15(4):369-76.
• [44]Sander B, Kwong JC, Bauch CT, McGeer A, Raboud JM, Krahn M. Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med. 2010;7(4), e1000256. doi:10.1371/journal.pmed.1000256.
• [45]Moran K, Maaten S, Guttmann A, Northrup D, Kwong JC. Influenza vaccination rates in Ontario children: implications for universal childhood vaccination policy. Vaccine. 2009;27(17):2350–5. doi:10.1016/j.vaccine.2009.02.017.
• [46]Jefferson T, Rivetti A, Harnden A et al.. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008; 2: Article ID CD004879
• [47]Jefferson T, Di Pietrantonj C, Rivetti A et al.. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010; 7: Article ID CD001269
• [48]Jefferson T, Di Pietrantonj C, Al-Ansary LA, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010(2):Cd004876. doi:10.1002/14651858.CD004876.pub3.
• [49]Jain VK, Rivera L, Zaman K et al.. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med. 2013; 369(26):2481-91.
• [50]Jimenez-Jorge S, de Mateo S, Delgado-Sanz C et al.. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011–2012 season in Spain, among population targeted for vaccination. BMC Infect Dis. 2013; 13:441. BioMed Central Full Text
• [51]Canadian Institute for Health Information. Patient Cost Estimator. Available at: http://www.cihi.ca/. Accessed on: 1-December-2014.
• [52]Skowronski DM, Woolcott JC, Tweed SA et al.. Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada. Vaccine. 2006; 24(19):4222-32.
• [53]National Health Services. The Information Centre for Health and Social care. Prescription cost analysis, England 2011. Avaiable at: http://www.hscic.gov.uk/catalogue/PUB05807/pres-cost-anal-eng-2011-rep.pdf. Accessed on: 1-April-2014.
• [54]British National Formulary. Available at: www.bnf.org. Accessed on: 1-April-2014.
• [55]Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. Available at: http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf. Accessed on: 8-April-2014.
• [56]National Institute for Health and Clinical Excellence. Discounting of health benefits in special circumstances. Available at: http://www.nice.org.uk/article/pmg9. Accessed on: 8-April-2014.
• [57]Rawlins M, Barnett D, Stevens A. Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol. 2010; 70(3):346-9.
• [58]Kwong JC, Stukel TA, Lim J et al.. The effect of universal influenza immunization on mortality and health care use. PLoS Med. 2008; 5(10): Article ID e211